This post was originally published on this site

Neuroscience has had a tough run of news lately. With Amgen deprioritizing neuro this year, Pfizer doing the same last year, and others like BMS, GSK, and AZ cutting back on CNS a few years earlier, it would seem dark times for neuroscience R&D. Add to that the recent unpredictable complexity around Biogen’s aducanumab, where hugely expensive PhaseRead More »

The post The Promise Of Precision Neuroscience And Launch Of Arkuda Therapeutics appeared first on Atlas Venture.